APO Research
Talk to an analyst

APO RESEARCH · REPORT

Anti-VEGF Drugs for the Treatment of Wet AMD

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Anti-VEGF Drugs for the Treatment of Wet AMD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

27 December 2025185 pages

Choose your research edition.

Industry ResearchAnti-VEGF Drugs for the Treatment of Wet AMD Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Industry Growth and Trends Forecast to 203293 pages · $3,450 USDMarket StructureGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032185 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Anti-VEGF Drugs for the Treatment of Wet AMD Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Anti-VEGF Drugs for the Treatment of Wet AMD market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Anti-VEGF Drugs for the Treatment of Wet AMD is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Anti-VEGF Drugs for the Treatment of Wet AMD include Chengdu Kanghong Pharmaceutica, Samsung Bioepis, Roche, Regeneron Pharmaceuticals, Novartis, Coherus BioSciences and Biocon Biologics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Anti-VEGF Drugs for the Treatment of Wet AMD market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Anti-VEGF Drugs for the Treatment of Wet AMD and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Anti-VEGF Drugs for the Treatment of Wet AMD sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Anti-VEGF Drugs for the Treatment of Wet AMD market size, projected growth trends, production technologies, key applications, and end-use industries.

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Company

Chengdu Kanghong Pharmaceutica

Samsung Bioepis

Roche

Regeneron Pharmaceuticals

Novartis

Coherus BioSciences

Biocon Biologics

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Type

Single target Drugs

Multi-target Drugs

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Application

Hospital and Clinic

Retail Pharmacies

Other

Anti-VEGF Drugs for the Treatment of Wet AMD Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Anti-VEGF Drugs for the Treatment of Wet AMD market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Anti-VEGF Drugs for the Treatment of Wet AMD and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Anti-VEGF Drugs for the Treatment of Wet AMD.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Anti-VEGF Drugs for the Treatment of Wet AMD market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Anti-VEGF Drugs for the Treatment of Wet AMD manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Anti-VEGF Drugs for the Treatment of Wet AMD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Anti-VEGF Drugs for the Treatment of Wet AMD in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends Table 2. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers Table 3. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges Table 4. Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints Table 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Manufacturers Table 9. Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Anti-VEGF Drugs for the Treatment of Wet AMD Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers, Product Type & Application Table 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Single target Drugs Table 17. Major Manufacturers of Multi-target Drugs Table 18. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 19. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2026) & (K Units) Table 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2027-2032) & (K Units) Table 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2026) Table 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2027-2032) Table 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2026) & (K Units) Table 25. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2027-2032) & (K Units) Table 26. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2026) Table 27. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospital and Clinic Table 29. Major Manufacturers of Retail Pharmacies Table 30. Major Manufacturers of Other Table 31. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 32. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2026) & (K Units) Table 33. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2027-2032) & (K Units) Table 34. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2026) Table 35. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2027-2032) Table 36. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 37. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2026) & (K Units) Table 38. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2027-2032) & (K Units) Table 39. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2026) Table 40. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2027-2032) Table 41. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 42. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026) & (K Units) Table 43. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Region (2021-2026) Table 44. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecasted by Region (2027-2032) & (K Units) Table 45. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecasted Market Share by Region (2027-2032) Table 46. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 47. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 48. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 49. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 51. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 52. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 54. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 55. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2026) & (K Units) Table 57. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2027-2032) & (K Units) Table 58. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 59. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2021-2026) & (US$ Million) Table 60. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2027-2032) & (US$ Million) Table 61. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021-2026) Table 62. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2027-2032) Table 63. Chengdu Kanghong Pharmaceutica Company Information Table 64. Chengdu Kanghong Pharmaceutica Business Overview Table 65. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 67. Chengdu Kanghong Pharmaceutica Recent Development Table 68. Samsung Bioepis Company Information Table 69. Samsung Bioepis Business Overview Table 70. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 72. Samsung Bioepis Recent Development Table 73. Roche Company Information Table 74. Roche Business Overview Table 75. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 77. Roche Recent Development Table 78. Regeneron Pharmaceuticals Company Information Table 79. Regeneron Pharmaceuticals Business Overview Table 80. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 82. Regeneron Pharmaceuticals Recent Development Table 83. Novartis Company Information Table 84. Novartis Business Overview Table 85. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 87. Novartis Recent Development Table 88. Coherus BioSciences Company Information Table 89. Coherus BioSciences Business Overview Table 90. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 92. Coherus BioSciences Recent Development Table 93. Biocon Biologics Company Information Table 94. Biocon Biologics Business Overview Table 95. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 96. Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio Table 97. Biocon Biologics Recent Development Table 98. Key Raw Materials Table 99. Raw Materials Key Suppliers Table 100. Anti-VEGF Drugs for the Treatment of Wet AMD Distributors List Table 101. Anti-VEGF Drugs for the Treatment of Wet AMD Customers List Table 102. Research Programs/Design for This Report Table 103. Authors List of This Report Table 104. Secondary Sources Table 105. Primary Sources List of Figures Figure 1. Anti-VEGF Drugs for the Treatment of Wet AMD Product Image Figure 2. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size (2021-2032) & (US$ Million) Figure 4. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales (2021-2032) & (K Units) Figure 5. Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Anti-VEGF Drugs for the Treatment of Wet AMD Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Single target Drugs Image Figure 9. Multi-target Drugs Image Figure 10. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 11. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2032) Figure 13. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2032) Figure 16. Hospital and Clinic Image Figure 17. Retail Pharmacies Image Figure 18. Other Image Figure 19. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 20. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share 2021 VS 2025 VS 2032 Figure 21. Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2032) Figure 22. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share 2021 VS 2025 VS 2032 Figure 24. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2032) Figure 25. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 26. North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2032) Figure 27. U.S. Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 28. Canada Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 29. Mexico Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2032) Figure 32. Germany Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 33. France Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 34. U.K. Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 35. Italy Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 36. Netherlands Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2032) Figure 39. China Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Japan Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 41. South Korea Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Southeast Asia Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 43. India Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Australia Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 45. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 46. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Country (2021-2032) Figure 47. Brazil Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 49. Saudi Arabia Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 50. Turkey Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Argentina Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 52. UAE Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Egypt Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Chile Anti-VEGF Drugs for the Treatment of Wet AMD Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 57. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Figure 58. North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 59. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Figure 60. Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Figure 62. Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032) & (US$ Million) Figure 64. South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Figure 66. Manufacturing Cost Structure Figure 67. Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process Figure 68. Direct Comparison with Distribution Share Figure 69. Distributors Profiles Figure 70. Years Considered Figure 71. Research Process Figure 72. Key Executives Interviewed

Scope & coverage.

Types
  • Single target Drugs
  • Multi-target Drugs
Applications
  • Hospital and Clinic
  • Retail Pharmacies
  • Other
Companies covered
  • Chengdu Kanghong Pharmaceutica
  • Samsung Bioepis
  • Roche
  • Regeneron Pharmaceuticals
  • Novartis
  • Coherus BioSciences
  • Biocon Biologics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market Dynamics
  1. 2.1 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Trends
  2. 2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Drivers
  3. 2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Opportunities and Challenges
  4. 2.4 Anti-VEGF Drugs for the Treatment of Wet AMD Industry Restraints
3 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Manufacturers
  1. 3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Manufacturers (2021-2026)
  3. 3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Anti-VEGF Drugs for the Treatment of Wet AMD Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers, Product Type & Application
  7. 3.7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Anti-VEGF Drugs for the Treatment of Wet AMD Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Anti-VEGF Drugs for the Treatment of Wet AMD Tier 1, Tier 2, and Tier 3
4 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Type
  1. 4.1 Anti-VEGF Drugs for the Treatment of Wet AMD Type Introduction
  2. 4.1.1 Single target Drugs
  3. 4.1.2 Multi-target Drugs
  4. 4.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type
  5. 4.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Type (2021-2032)
  7. 4.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Type (2021-2032)
  8. 4.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type
  9. 4.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Type (2021-2032)
  11. 4.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Type (2021-2032)
5 Anti-VEGF Drugs for the Treatment of Wet AMD Market by Application
  1. 5.1 Anti-VEGF Drugs for the Treatment of Wet AMD Application Introduction
  2. 5.1.1 Hospital and Clinic
  3. 5.1.2 Retail Pharmacies
  4. 5.1.3 Other
  5. 5.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application
  6. 5.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Application (2021-2032)
  8. 5.2.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Market Share by Application (2021-2032)
  9. 5.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application
  10. 5.3.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Application (2021-2032)
  12. 5.3.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Application (2021-2032)
6 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region
  1. 6.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2032)
  3. 6.2.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Region (2021-2026)
  4. 6.2.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region
  1. 7.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region
  2. 7.1.1 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2021-2026)
  4. 7.1.3 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue by Region (2027-2032)
  5. 7.1.4 Global Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032)
  8. 7.2.2 North America Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032)
  11. 7.3.2 Europe Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Anti-VEGF Drugs for the Treatment of Wet AMD Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Chengdu Kanghong Pharmaceutica
  2. 8.1.1 Chengdu Kanghong Pharmaceutica Company Information
  3. 8.1.2 Chengdu Kanghong Pharmaceutica Business Overview
  4. 8.1.3 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Chengdu Kanghong Pharmaceutica Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  6. 8.1.5 Chengdu Kanghong Pharmaceutica Recent Developments
  7. 8.2 Samsung Bioepis
  8. 8.2.1 Samsung Bioepis Company Information
  9. 8.2.2 Samsung Bioepis Business Overview
  10. 8.2.3 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Samsung Bioepis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  12. 8.2.5 Samsung Bioepis Recent Developments
  13. 8.3 Roche
  14. 8.3.1 Roche Company Information
  15. 8.3.2 Roche Business Overview
  16. 8.3.3 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Roche Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  18. 8.3.5 Roche Recent Developments
  19. 8.4 Regeneron Pharmaceuticals
  20. 8.4.1 Regeneron Pharmaceuticals Company Information
  21. 8.4.2 Regeneron Pharmaceuticals Business Overview
  22. 8.4.3 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Regeneron Pharmaceuticals Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  24. 8.4.5 Regeneron Pharmaceuticals Recent Developments
  25. 8.5 Novartis
  26. 8.5.1 Novartis Company Information
  27. 8.5.2 Novartis Business Overview
  28. 8.5.3 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Novartis Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  30. 8.5.5 Novartis Recent Developments
  31. 8.6 Coherus BioSciences
  32. 8.6.1 Coherus BioSciences Company Information
  33. 8.6.2 Coherus BioSciences Business Overview
  34. 8.6.3 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Coherus BioSciences Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  36. 8.6.5 Coherus BioSciences Recent Developments
  37. 8.7 Biocon Biologics
  38. 8.7.1 Biocon Biologics Company Information
  39. 8.7.2 Biocon Biologics Business Overview
  40. 8.7.3 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Biocon Biologics Anti-VEGF Drugs for the Treatment of Wet AMD Product Portfolio
  42. 8.7.5 Biocon Biologics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Anti-VEGF Drugs for the Treatment of Wet AMD Value Chain Analysis
  2. 9.1.1 Anti-VEGF Drugs for the Treatment of Wet AMD Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Anti-VEGF Drugs for the Treatment of Wet AMD Production Mode & Process
  6. 9.2 Anti-VEGF Drugs for the Treatment of Wet AMD Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Anti-VEGF Drugs for the Treatment of Wet AMD Distributors
  9. 9.2.3 Anti-VEGF Drugs for the Treatment of Wet AMD Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst